72 related articles for article (PubMed ID: 38556596)
1. Non-canonical functions of the mitotic kinesin Eg5.
Liu M; Ran J; Zhou J
Thorac Cancer; 2018 Aug; 9(8):904-910. PubMed ID: 29927078
[TBL] [Abstract][Full Text] [Related]
2. Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy.
Myers SM; Collins I
Future Med Chem; 2016; 8(4):463-89. PubMed ID: 26976726
[TBL] [Abstract][Full Text] [Related]
3. Identifying and characterising promising small molecule inhibitors of kinesin spindle protein using ligand-based virtual screening, molecular docking, molecular dynamics and MM‑GBSA calculations.
Elseginy SA
J Comput Aided Mol Des; 2024 Apr; 38(1):16. PubMed ID: 38556596
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket.
Gao C; Lowndes NF; Eriksson LA
ACS Omega; 2017 May; 2(5):1836-1849. PubMed ID: 30023646
[TBL] [Abstract][Full Text] [Related]
5. Lead Generation for Human Mitotic Kinesin Eg5 Using Structure-based Virtual Screening and Validation by In-vitro and Cell-based Assays.
Makala H; Alexandar SP; Nagarajan D; Mahapatra SK; Ulaganathan V
Curr Comput Aided Drug Des; 2021; 17(6):759-772. PubMed ID: 32703141
[TBL] [Abstract][Full Text] [Related]
6. Kolaflavanone, a biflavonoid derived from medicinal plant Garcinia, is an inhibitor of mitotic kinesin Eg5.
Alrazi IMD; Ogunwa TH; Kolawole AO; Elekofehinti OO; Omotuyi OI; Miyanishi T; Maruta S
J Biochem; 2021 Dec; 170(5):611-622. PubMed ID: 34264310
[TBL] [Abstract][Full Text] [Related]
7. Binding patterns of inhibitors to different pockets of kinesin Eg5.
Jia N; Zhang B; Huo Z; Qin J; Ji Q; Geng Y
Arch Biochem Biophys; 2024 Jun; 756():109998. PubMed ID: 38641233
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates: Recent advances in payloads.
Wang Z; Li H; Gou L; Li W; Wang Y
Acta Pharm Sin B; 2023 Oct; 13(10):4025-4059. PubMed ID: 37799390
[TBL] [Abstract][Full Text] [Related]
10. Kinesin-5 inhibition improves neural regeneration in experimental autoimmune neuritis.
Kohle F; Ackfeld R; Hommen F; Klein I; Svačina MKR; Schneider C; Fink GR; Barham M; Vilchez D; Lehmann HC
J Neuroinflammation; 2023 Jun; 20(1):139. PubMed ID: 37296476
[TBL] [Abstract][Full Text] [Related]
11. Computational Approaches to the Rational Design of Tubulin-Targeting Agents.
Pérez-Peña H; Abel AC; Shevelev M; Prota AE; Pieraccini S; Horvath D
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830654
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of novel microtubule suppressors with an imidazopyridine scaffold through structure-based virtual screening and docking.
Elseginy SA; Oliveira ASF; Shoemark DK; Sessions RB
RSC Med Chem; 2022 Aug; 13(8):929-943. PubMed ID: 36092142
[TBL] [Abstract][Full Text] [Related]
13. Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies.
Shahin R; Aljamal S
Future Sci OA; 2022 Mar; 8(3):FSO778. PubMed ID: 35251692
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation for Identification of a Novel DNA Gyrase B Inhibitor with Benzoxazine Acetamide Scaffold.
Elseginy SA; Anwar MM
ACS Omega; 2022 Jan; 7(1):1150-1164. PubMed ID: 35036778
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
